Available from: Cynthia Behling, Apr 30, 2015
  • Source
    • "(B) Portal/periportal fibrosis (Masson's trichrome, 10ϫ). activity, especially to compare a liver biopsy in longitudinal studies assessing histological changes, but they should not be considered a tool for establishing the diagnosis or as replacement of pathologist's evaluation [27] [44] "
    [Show abstract] [Hide abstract]
    ABSTRACT: Nonalcoholic fatty liver disease is rapidly becoming one of the most common liver diseases in the pediatric population in industrialized countries because of the growing prevalence of obesity and overweight. For this reason, there is a keen and broad interest among researchers to identify new diagnostic noninvasive tools and novel treatment modalities for this condition. Unfortunately, to date, liver biopsy remains the imperfect gold standard for diagnosis. In addition, available noninvasive markers are not fully satisfactory for the diagnosis of fatty liver. Although in recent years many pharmacological agents, on the basis of pathogenetic mechanism of the disease, have been attempted, to date, the guidelines for the management of fatty liver are still lacking. Establishing effective therapeutic strategies to treat the disease represents the challenge for pediatric hepatologists in the near future. In this article, we briefly review the current knowledge and ideas concerning pediatric nonalcoholic fatty liver disease, and discuss the new perspective therapies.
    Journal of Adolescent Health 10/2012; 51(4):305–312. DOI:10.1016/j.jadohealth.2012.01.010 · 3.61 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: See article in J. Gastroenterol. Hepatol. 2012; 27: 142-148.
    Journal of Gastroenterology and Hepatology 01/2012; 27(1):5-7. DOI:10.1111/j.1440-1746.2011.06957.x · 3.50 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Non-alcoholic fatty liver disease (NAFLD) is the most common chronic liver disease in the Western world. It is closely associated with metabolic syndrome. The alarming epidemics of diabetes and obesity have fueled an increasing prevalence of NAFLD, particularly among these high-risk groups. Histologically, NAFLD encompasses a disease spectrum ranging from simple steatosis to non-alcoholic steatohepatitis (NASH), which is characterized by hepatocyte injury, inflammation, and variable degrees of fibrosis on liver biopsy. Non-alcoholic steatohepatitis can progress to cirrhosis in a fraction of patients. There is currently little understanding of risk factors for disease progression and the disease pathogenesis has not been fully defined. Liver biopsy remains the gold standard for diagnosis. Weight loss, dietary modification, and the treatment of underlying metabolic syndrome remain the mainstays of therapy once the diagnosis is established. There are no well-established pharmacological agents for treatment of NASH, although this is a subject of ongoing research.
    Journal of Diabetes 05/2012; 4(3):266-80. DOI:10.1111/j.1753-0407.2012.00204.x · 1.93 Impact Factor
Show more